Chattem Cites “Dearth Of Good Brands” For Quiet M&A Activity
This article was originally published in The Tan Sheet
Executive Summary
A string of settled PPA and ephedra cases will allow Chattem to focus more of its bottom line on product development and potential acquisitions
You may also be interested in...
Metabolife Liability Reversal Offers Precedent For Ephedra Defendants
Defendants' prospects in future ephedra liability suits may have been strengthened by a FDL-1federal appeals court reversal of a $4.1 mil. jury award against Metabolife
Chattem Unlikely To Buy Bristol Brands Due To Excedrin Aversion
Chattem would consider buying one of the smaller brands in Bristol-Myers Squibb's consumer medicines unit, excluding Excedrin, President & COO Alec Taylor reported during a Jan. 20 earnings call
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC